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Introduction
The high-mobility group box-1 (HMGB1) protein is
present in almost all eukaryotic cells [1]. It was identi-
fied in the nucleus and in the cytoplasm of several cells.
Within the nucleus, HMGB1 stabilizes nucleosomes
and regulates transcription of many genes [2]. As a
cytokine-like factor, HMGB1 is secreted by
macrophages, mature dendritic cells and natural killer
cells  in response to injury, infection, or other inflam-
matory stimuli [3,4]. The biological importance of
HMGB1 is underscored by its multifunctionality, as
well as pathologic conditions caused in a man by its
deregulation: Alzheimer's Disease [5], arthritis [6], and
cancer [7]. HMGB1 release into the extracellular envi-
ronment is mediated by active and passive mecha-
nisms. The passive release of HMGB1 into the extra-
cellular space occurs during unscheduled cell death,
where HMGB1 diffuses out of the leaky membranes of
the necrotic cells [8]. In this role, HMGB1 serves as a
''necrotic marker'' or a damage-associated molecular
pattern for recognition by cells of the innate immune
system and is a surrogate for the extent of injury, initi-
ating tissue repair [6]. The passive release of HMGB1
is not observed during type I apoptotic cell death, in
which HMGB1 is tightly sequestered within apoptotic
bodies, thereby preventing its release [6]. Outside the
cell, HMGB1 masquerades as a cytokine to activate
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endothelial cells, promoting angiogenesis and extravas-
cular emigration of inflammatory cells and stem cells,
thereby initiating inflammation [9]. Several receptors
have been identified for HMGB1 including RAGE,
TLR2, TLR4, syndecan and a specific receptor-tyrosine
phosphatase [10]. The signaling mechanisms and end
events of these receptor interactions have not been
explained completely yet. A variety of human neo-
plasms, including breast, colorectal, hepatocellular, pan-
creatic and lung cancer overexpress HMGB1 [11]. There
are no data about serum levels of  HMGB1 in lung can-
cer  patients during chemotherapy and only few reports
about correlations between  HGMB 1 and angiogenic
factors determined in serum e.g., VEGF and survivin. A
vascular endothelial growth factor (VEGF), apparently
the most important angiogenic factor, is a prime regula-
tor of both physiological and pathological angiogenesis
in malignancy [12]. Survivin is an unique inhibitor of
apoptosis, selectively expressed in most human cancers,
but undetectable in normal adult tissues [13]. In addition
to its direct role in carcinogenesis, survivin may also
play a key role in tumor angiogenesis because it is
strongly expressed in endothelial cells during the remod-
eling and proliferative phase of angiogenesis [14].
Recent studies  have also suggested that survivin plays a
role in tumor progression and chemoresistance [15].
Materials and methods
Patients. The study involved 40 patients diagnosed and treated in
the Department of Lung Diseases and Tuberculosis in Bialystok
(31 men and 9 women) with the histological diagnosis of NSCLC.
The mean age of patients was 60.7 ± 3 years. The study patients
had neither been treated with any anticancer medication nor under-
gone radiotherapy. Squamous cell carcinoma (SCC) comprised
42.5% (17 individuals) of patients with NSCLC, adenocarcinoma
was revealed in 27.5% (11 patients), whereas NSCLC was diag-
nosed in 30% (12 patients). Serum samples obtained from the
whole blood of patients with lung cancer before cytoreduction
treatment and after four cycles of chemotherapy, were used as the
study material. To exclude the possible interference of chemother-
apy, subsequent blood samples were obtained at least 28 days after
the last administration of cytotoxic drugs. Blood serum was stored
at -80°C immediately after separation by centrifugation (3000 rpm)
until the assay was performed. At the first stage, blood samples
were taken to assess HMGB1, survivin, and VEGF after complete
diagnostics of lung cancer had been made, including X-ray and CT
of the chest, bronchofiberscopy with H-P test, lung transbronchial
biopsy (TBB), or transbronchial needle aspiration biopsy (TBNA).
The clinical analysis comprised the evaluation of clinical staging
of NSCLC (TNM, AJCC), and the performance stage according to
Zubrod. The response to therapy was estimated according to the
WHO criteria. All patients underwent basic laboratory tests and
accessory investigations (ultrasonography of the abdominal cavity,
if necessary, of the chest, EEG, and CT of the central nervous sys-
tem). At the next stage, after termination of chemotherapy, during
the evaluation of therapy outcome, blood samples were collected to
determine the concentrations of HMGB1, survivin, and VEGF. 
Control subjects. The control group consisted of 15 healthy vol-
unteers (12 men and 3 women) without any acute or chronic
inflammatory conditions. The mean age of controls at the time of
sampling was 62.1 ± 4 years. There were no significant differences
in age and sex between patients and controls.
Therapy. Chemotherapy was carried out in a 21-day cycle using cis-
platin at a dose of 30 mg /m2 on days 1, 2, and 3 and gemcytabine at
a dose of 1000 mg/m2 on days 1 and 8 of the cycle. All patients
received four cycles of chemotherapy. Some of the patients under-
went later radiotherapy or next cycles of chemotherapy.
Serum HMGB1, survivin, and VEGF analysis. HMGB1
(HMGB1 Elisa Kit II, Shino- Test Corp., Japan), survivin (Quan-
tikine Human survivin Immunoassay, R&D System, USA), and
VEGF (Quantikine Human VEGF Immunoassay, R&D System,
USA) concentrations were determined by means of an enzyme-
linked immunosorbent assay (ELISA) method according to the
manufacturer's instructions. All specimens were assayed twice and
the average of the two measurements was used in the data analy-
sis. The minimum detectable dose (MDD) of HMGB1 ranged from
2.5 to 80 ng/ml. The sensitivity was 1.0 ng/ml. The MDD of sur-
vivin ranged from 1.58 pg/ml to 9.96 pg/ml. The mean MDD was
4.44 pg/ml. The MDD of VEGF was less than 5.0 pg/ml. 
Ethical issues. In accordance with the declaration of Helsinki, the
study protocol was approved by the local ethics committee and
written informed consent was obtained from all participants.
Statistical analysis. Statistical analysis was performed using Sta-
tistica 8.0 software (Stat Soft Inc., Tulsa, USA). The compatibility
test of  Shapiro-Wilk was used for measurable features consistent
with normal distribution. The Student t test for paired and unpaired
samples was applied. Correlations between the parameters were
calculated by the Pearson's tests. Survival curves were generated
using the Kaplan-Meier method, and the significant difference in
survival rates was determined by the log-rank test. Multivariate
analysis was performed using the Cox proportional hazards model.
All patients with lung cancer were divided into two groups accord-
ing to their HMGB1, survivin, and VEGF serum levels. The cut-off
point was set at 2.38 ng/ml for HMGB1, 81.92 pg/ml for survivin,
and 443.26 pg/ml for VEGF. Receiver-operating characteristics
(ROC) curves were applied to find the cut-off level of HMGB1,
survivin, and VEGF. A value of p<0.05 was considered to be the
level of statistical significance.
Results
None of the prognostic parameters analyzed (Table 1)
was correlated significantly with the serum HMGB1,
survivin and VEGF  levels (p>0.05).
The levels of serum HMGB1, survivin and VEGF
in patients with advanced NSCLC and healthy controls
are shown in Table 2. The baseline serum HMGB1 and
VEGF levels were significantly higher in patients with
advanced NSCLC than in the control group (p=0.024,
p=0.028). survivin levels were not significantly differ-
ent from the healthy control group (p=0.705).  Con-
centrations of HMGB1, survivin and VEGF  did not
differ markedly before and after chemotherapy of lung
cancer (p=0.809, p=0.902 and p=0.409) (Table 3).  No
correlation was found between HMGB1, survivin and
VEGF concentrations and the histological type and
staging of lung cancer. Patients in group IIIB had the
same concentrations of HMGB1, survivin and VEGF
as patients in group IV.
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In the group of patients, PR (Partial Response) was
reported in 16 patients (40%), stabilization (NC, No
Change) in 10 patients (25%), and PD (Progressive
Disease) in 14 patients (35%). No correlation was found
between the concentrations of HMGB1, survivin and
VEGF and the effect of chemotherapy (Tables 4 and 5). 
A positive correlation between HMGB1  and sur-
vivin concentrations (R=0.814, p=0.007) in patients
with lung cancer before treatment; a negative corre-
lation  between HMGB1 and VEGF concentrations
(R=-0.841, p=0.035) in patients with lung cancer after
treatment were found.
When all patients with lung cancer were divided
into high and low groups using cut-off serum HMGB1,
survivin and VEGF  concentrations, the prognoses of
high and low groups were not different. The cut-off
serum concentrations were 2.38 ng/ml for HMGB1
(Fig. 1), 81.92 pg/ml for survivin (Fig. 2) and 443.26
pg/ml for VEGF (Fig. 3). The mean survival time of all
patients  was 11.3 months. Older age, weight loss, and
performance status yielded a prognostic value (p=0.023,
p=0.001, p=0.002, respectively) (Table 6). Conversely,
neither HMGB1, survivin nor VEGF levels were
proved to be significant for the survival time.
ROC (Receiver Operating Characteristic) curve
analysis was performed  to assess the effectiveness
of serum HMGB1 and VEGF determination  used to
discriminate between NSCLC and controls (Fig. 4).
The AUCs of  HMGB1, survivin and VEGF were
respectively: 0.763, 0.764, 0.752 and all of them
were higher than 0.5 (p=0.035; p=0.021; p=0.012).
ROC curves showed that circulating HMGB1 and
VEGF serum level did not demonstrate a high sensi-
tivity-specificity relationship, and therefore, had a
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Table 1. Patients' characteristics
Abbreviations: n – number; SD – standard deviation
Abbreviations: n – number; SD – standard deviation
Table 3. Distribution of serum values of HMGB1, Survivin and
VEGF in patients with NSCLC  before and after chemotherapy
disease by Student's T – test for paired samples.
Abbreviations: n – number; SD – standard deviation
Table 4. Distribution of serum values of  HMGB1, survivin and
VEGF before and after chemotherapy, in patients with partial
response or stable disease by student's t – test for paired samples
(subgroup analysis).
Abbreviations: n – number; SD – standard deviation
Table 5. Distribution of serum values of  HMGB1, Survivin and
VEGF before and after chemotherapy, in patients with progressive
disease by student's t – test for paired samples (subgroup analysis).
Abbreviations: n – number; SD – standard deviation
Table 2. Distribution of serum HMGB1, Survivin and VEGF val-
ues in patients with NSCLC and  healthy controls by student's 
t – test for unpaired samples.
low ability to differentiate NSCLC from healthy per-
sons. The cut off values of HMGB1, survivin and
VEGF were established at 1.75 ng/ml; 156.7 pg/ml;
307.64 pg/ml (ROC curves), respectively. There
were no significant differences between the areas
under the curves.
Discussion
Neoangiogenesis plays a key role in a tumor's growth.
VEGF as well as  survivin and  HMGB1, described
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Fig. 1. Probability of survival for lung
cancer patients in relation to serum
HMBG1 levels (before chemotherapy).
Fig. 2. Probability of survival for lung
cancer patients in relation to serum
Survivin levels (before chemotherapy).
Table 6. Influence of statistically significant prognostic factors
and serum parameters on survival in advanced NSCLC patients
lately are the most important growth factors involved in
this process. Recently, several reports have suggested
that HMGB1 plays a key role in tumor angiogenesis
through multiple mechanisms, including up-regulation
of proangiogenic factors, promoting endothelial pro-
genitor cells homing to ischemic tumor tissues and
induction of endothelial cell migration and sprouting
[16]. The correlations between serum concentrations:
HMGB1 and survivin as well as HMGB1 and VEGF,
obtained in our study, demonstrate  mutual inter-rela-
tions between angiogenic factors mentioned above.
Hypoxia is a common phenomenon in human solid
tumors as a result of the rapid growth rate of the tumor
cells [16]. Chronic hypoxia often leads to necrotic
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Fig. 3. Probability of survival for lung
cancer patients in relation to serum
VEGF levels (before chemotherapy).
Fig. 4. ROC curves of HMGB 1, survivin and VEGF
(for discrimination between NSCLC and controls).
regions, in which HMGB1 rapidly leaks out from per-
meable  necrotic tumor cells. Meanwhile, tumor-asso-
ciated macrophages accumulated in the hypoxic tumor
regions could be activated by HMGB1, resulting in
secretion of angiogenic factors, including a vascular
endothelial growth factor (VEGF), and thereby pro-
moting tumor angiogenesis [17]. Thus, patients with
lung cancer have the higher concentration of VEGF in
serum, which was confirmed in our study and by many
other researchers [18]. The high circulating serum vas-
cular endothelial growth factor (VEGF) levels might
reflect enhanced angiogenesis in patients suffering
from non-small cell lung cancer (NSCLC).  
In the study, it was proved for the first time that
patients with lung cancer had the higher serum  con-
centration of  HMGB1 than healthy people. The stud-
ies to date on HMGB1 in patients with lung cancer
concerned explicitly the expression in tumor tissues.
HMGB1 binds RAGE (receptor for advanced gly-
cation end products) receptor to initiate many cellular
processes [17]. Non-small cell carcinoma studies
established a role for RAGE in the regulation of dif-
ferentiation in the lung tissue characterized by down-
regulation of RAGE [19]. The loss of HMGB1-RAGE
-mediated regulation of tumor cell migration and inva-
sive processes are associated with increased aggres-
siveness of tumor behavior in the lung [19,20].
The lower involvement of HGMB1 in binding with
RAGE receptor may contribute to the growth of this
protein in blood serum, which is in accordance with
the results of our study. Patients with  NSCLC had
higher concentrations of  HMGB1 than healthy people.
However, active myeloid cells, NK cells and cytotoxic
T cells secreted from macrophages and monocytes
may contribute  to the growth of this protein (during
anti-neoplastic T-cell responses) [21].  Apoptosis also
contributes to an increase in HMGB1 serum concen-
tration – a massive 'throw' of  HMGB1 from the
decomposition of tumor cells, present previously in the
nucleus and cytoplasm.
One of the inhibitors of apoptosis is survivin. It also
promotes cell proliferation and induces angiogenesis
[22]. survivin shows a significant difference in the
expression between malignant and normal adult cells,
with very low to absent levels in the normal adult tis-
sue but increased levels in a wide variety of solid
tumors [23]. In tumors, the positive expression of sur-
vivin correlates with more aggressive behavior and
poorer prognosis [24]. Our study based on the meas-
urements of survivin concentrations in serum did not
confirm these observations. We proved that survivin
concentrations were the same in patients with NSCLC
as in healthy people  and were not related to the prog-
nosis of survival time. These results were in agreement
with Fan's et al. findings [25] and studies among
patients with other cancers [26].
Similarly, we indicated that determination of
serum concentrations of  HGMB1 during chemothera-
py was useless for the prognosis of survival time and
the effect of chemotherapy. In patients with colorectal
cancer, the  enhanced expression of HMGB1 was
proved to correlate with poor prognosis [27].
A lack of correlations between HMGB1 concentra-
tions and survival time, staging and an effect of
chemotherapy may be due to complex mechanisms
and interrelations that cause HMGB1 release to the
blood. On the one hand, these are mechanisms respon-
sible for cell death  (apoptosis, autophagy, necrosis),
on the other, the reaction of inflammatory cells and the
immune system to the growing tumor [1]. 
Besides endothelial cells, VEGF is secreted by sev-
eral cell types such as, macrophages, stromal cells,
epithelial cells of the retina, and malignant cells [28].
Nevertheless, hypoxia is not the only cause of VEGF
production  by a tumor [28]. The increased VEGF
gene expression has also been reported after inactiva-
tion of p53 or  RAS mutations, and after expression
of the oncogene Src [29]. The tumor angiogenesis can
also be regulated by various exogenous factors which
modulate the VEGF production, thereby exercising
an indirect angiogenic effect [28]. These complex
mechanisms influencing  serum VEGF concentration
might have contributed to the fact that we did not
prove correlations between  VEGF concentrations,
and the effect of therapy and prognosis of survival
time. The results of our study are in accordance with
Chakra's et al.[30] and Tas's et al [31] findings. These
authors proved that a circulating serum vascular
endothelial growth factor was not a prognostic factor
of non-small cell lung cancer. Conversely, Dudek et
al [18] found the correlation between   the concentra-
tion of VEGF  and  the treatment response and sur-
vival time  and high levels of serum VEGF at the time
of presentation with NSCLC might predict worse sur-
vival.
Summing up, patients with lung cancer have a
higher serum concentration of HMGB1 and VEGF in
comparison with healthy people. The levels of survivin
in serum of NSCLC patients are comparable to this of
healthy people.  In our opinion, determination of
HMGB1, survivin and VEGF  concentrations has no
clinical significance in the prognosis of the survival
time in lung cancer.
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